OHSU

Clinical Trials

Clinical trials are research studies in which people help doctors find ways to improve health and cancer care. Each study tries to answer scientific questions and to find better ways to prevent, diagnose, or treat cancer. We provide you access to a wide variety of clinical trials and continue to open new trials as they become available. We are committed to providing innovative treatments at our community clinics.

 

IRB 8373 (OPEN)
A Prospective, Longitudinal, Observation Study in Newly Diagnosed Multiple Myeloma Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles

IRB 9761 (OPEN)
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

IRB 10122 (OPEN)
CBKM120ZUS40: Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-activated tumors

IRB 10426 (OPEN)
Modular Phase 2 Study to Link Atrageted Therapy to Patients with Pathway Activated Tumors: Module 3-MEK162 for Patients with RAS/RAF/MEK Activated Tumors

IRB 9936 (OPEN)
ARRAY-520-216: A Multicenter, Randomized, Open-label, Non-comparative Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma

IRB 10427 (OPEN)
Modular Phase II Study to Link Targeted Theraoy to Patients with Pathway Activated Tumors: Module 4-LGX818 for Patients with BRAFV600E Mutated Tumors

IRB 10653 (OPEN)
Module Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

IRB 10489 (OPEN)
Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The "METRIC" Study)

IRB 10028 (OPEN)
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients with KRAS Mutant Non-Small Cell Lung Cancer

IRB 9363 (OPEN)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (SPARTAN TRIAL)